Kymera Therapeutics Inc (NASDAQ: KYMR) has seen a rise in its stock price by 6.96 in relation to its previous close of 30.70. However, the company has experienced a 31.24% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-22 that Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., April 22, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BroADen Phase 1b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe atopic dermatitis (AD).
Is It Worth Investing in Kymera Therapeutics Inc (NASDAQ: KYMR) Right Now?
Moreover, the 36-month beta value for KYMR is 2.14. Analysts have varying opinions on the stock, with 14 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for KYMR is 53.88M and currently, short sellers hold a 14.83% of that float. On April 24, 2025, KYMR’s average trading volume was 697.50K shares.
KYMR’s Market Performance
KYMR stock saw an increase of 31.24% in the past week, with a monthly gain of 3.19% and a quarterly increase of -25.76%. The volatility ratio for the week is 6.10%, and the volatility levels for the last 30 days are 9.21% for Kymera Therapeutics Inc (KYMR). The simple moving average for the last 20 days is 26.42% for KYMR stock, with a simple moving average of -19.74% for the last 200 days.
Analysts’ Opinion of KYMR
Many brokerage firms have already submitted their reports for KYMR stocks, with Citigroup repeating the rating for KYMR by listing it as a “Buy.” The predicted price for KYMR in the upcoming period, according to Citigroup is $52 based on the research report published on March 13, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see KYMR reach a price target of $60. The rating they have provided for KYMR stocks is “Buy” according to the report published on December 10th, 2024.
BMO Capital Markets gave a rating of “Market Perform” to KYMR, setting the target price at $55 in the report published on December 06th of the previous year.
KYMR Trading at 6.93% from the 50-Day Moving Average
After a stumble in the market that brought KYMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.36% of loss for the given period.
Volatility was left at 9.21%, however, over the last 30 days, the volatility rate increased by 6.10%, as shares surge +7.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.88% lower at present.
During the last 5 trading sessions, KYMR rose by +30.82%, which changed the moving average for the period of 200-days by +2.41% in comparison to the 20-day moving average, which settled at $25.97. In addition, Kymera Therapeutics Inc saw -18.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYMR starting from Chiniara Ellen, who sale 2,241 shares at the price of $30.45 back on Mar 03 ’25. After this action, Chiniara Ellen now owns 80,085 shares of Kymera Therapeutics Inc, valued at $68,239 using the latest closing price.
Chadwick Jeremy G, the Chief Operating Officer of Kymera Therapeutics Inc, sale 1,383 shares at $30.45 during a trade that took place back on Mar 03 ’25, which means that Chadwick Jeremy G is holding 67,800 shares at $42,113 based on the most recent closing price.
Stock Fundamentals for KYMR
Current profitability levels for the company are sitting at:
- -5.45 for the present operating margin
- 0.89 for the gross margin
The net margin for Kymera Therapeutics Inc stands at -4.76. The total capital return value is set at -0.28. Equity return is now at value -36.38, with -28.81 for asset returns.
Based on Kymera Therapeutics Inc (KYMR), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -2.22. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -1030.96.
Currently, EBITDA for the company is -216.24 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 45.02. The receivables turnover for the company is 49.71for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.53.
Conclusion
To wrap up, the performance of Kymera Therapeutics Inc (KYMR) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
